Clinical Evidence and Approval Background

Ustekinumab is a monoclonal antibody that blocks interleukin‑12/23, and in pivotal Phase 3 trials demonstrated statistically significant skin improvement and safety in patients with moderate to severe psoriasis. These clinical data supported the European Medicines Agency (EMA) approval.

Positioning Relative to Competitor Drugs

Compared with the already established secukinumab (IL‑17 inhibitor), ustekinumab differentiates itself through longer durability of response and a 12‑week dosing interval. Fewer injections may improve treatment adherence from the patient perspective.

Reimbursement and Market Entry Challenges

National health insurance schemes across Europe require cost‑effectiveness analyses; therefore, the relatively high launch price of ustekinumab may delay reimbursement decisions. Consequently, actual prescribing volume will be heavily influenced by reimbursement policies.

Market Size and Growth Outlook

Although the source does not provide specific market size figures, the overall psoriasis therapeutic market generates several billion euros in revenue, suggesting a substantial potential market share for ustekinumab. Targeting patient populations that are insufficiently responsive to existing therapies could drive significant growth.